Extension of the expression of transgenic proteins by immunomodulation

The use of 15-deoxyspergualin, anti-T-cell antibody, corticosteriod, azathioprine, methotrexate or a compound of the formula (I) or (II)

• 2
• and/or an optionally stereoisomeric form of the compound of the:
• formula I or II and/or a physiologically tolerable salt of the compound of the formula I, is employed
• where
• R1 is
• a) (C1-C4)-alkyl,
• b) (C3-C5)-cycloalkyl,
• c) (C2-C6)-alkenyl or
• d) (C2-C6)-alkynyl,
• R2 is
• a) —CF3,
• b) —O—CF3,
• c) —S—CF3,
• d) —OH,
• e) —NO2,
• f) halogen,
• g) benzyl,
• h) phenyl,
• i) —O-phenyl,
• k) —CN or
• l) —O-phenyl, mono- or polysubstituted by
• 1) (C1-C4)-alkyl,
• 2) halogen,
• 3) —O—CF3 or
• 4) —O—CH3,
• R3 is
• a) (C1-C4)-alkyl,
• b) halogen, or
• c) a hydrogen atom, and
• X is
• a) a —CH group or
• b) a nitrogen atom,
• for the production of a pharmaceutical for increasing the tolerance of a mammal, in particular man, to transgenic cells, after discontinuing the immunosuppressant concomitant therapy, the transgenic cells being transfected by means of a recombinant adenovirus vector.